DT-2216 is under clinical development by Dialectic Therapeutics and currently in Phase I for Blood Cancer. According to GlobalData, Phase I drugs for Blood Cancer have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DT-2216’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DT-2216 is under development for the treatment of solid tumor and hematologic malignancy, fibrolamellar hepatocellular carcinoma, unspecified B-cell lymphomas and T-cell lymphoma. The drug candidate is a heterobifunctional PROTAC (proteolysis-targeting chimera), which acts by targeting VHL and BCLXL. It is administered through intravenous route and is developed using Antiapoptotic Protein Targeted Degradation (APTaD) technology.
Dialectic Therapeutics overview
Dialectic Therapeutics., is a biotechnology company that develops impactful anti-cancer drugs. The company is headquartered in United States.
For a complete picture of DT-2216’s drug-specific PTSR and LoA scores, buy the report here.